The end-game of strong-arming companies over prices at the expense of patients and process

The insistence that a company accept a dramatic cut as the price of securing a listing for an off-patent medicine for a degenerative neurological condition, when there is no legal or transparent policy basis for such a demand. That insistence has become an unwelcome feature of the system, particularly targeted at small, naive companies. …